Adjunctive therapy for severe malaria: a review and critical appraisal

Despite recent efforts and successes in reducing the malaria burden globally, this infection still accounts for an estimated 212 million clinical cases, 2 million severe malaria cases, and approximately 429,00...
Source: Malaria Journal - Category: Infectious Diseases Authors: Tags: Review Source Type: research

Related Links:

[The Herald] French President Emmanuel Macron reserved rare praise for Zimbabwe for its deepened fight against HIV, tuberculosis (TB) and malaria.
Source: AllAfrica News: Health and Medicine - Category: African Health Source Type: news
Publication date: January 2020Source: Materials Science and Engineering: C, Volume 106Author(s): Josias Boumbéwendin Gérard Yaméogo, Roseline Mazet, Denis Wouessidjewe, Luc Choisnard, Diane Godin-Ribuot, Jean-Luc Putaux, Rasmané Semdé, Annabelle GèzeAbstractArtemisinin and its derivatives are currently recommended by World Health Organization for the treatment of malaria. Severe malaria requires a parenteral administration of artemisinin-based formulations. However, the effective use of artemisinin is limited by the pharmacokinetic characteristics of the drug (low water solubility,...
Source: Materials Science and Engineering: C - Category: Materials Science Source Type: research
ConclusionsInformation on returning travellers, includes ensuring that the patients receive supervised treatment with the recommended dose of a quality controlled medicine, routine follow-up of all cases, assessment of adequate absorption of the drug, and/or testing the prevalence of molecular markers of drug resistance if validated, can be an important source of an early warning system for emerging resistance.
Source: IDCases - Category: Infectious Diseases Source Type: research
We reported three cases of possible parasite resistance to artemether-lumefantrine therapy. All subjects had complete parasite clearance when treated with other antimalarial drugs. This observation necessitates the urgent need to re-evaluate artemether-lumefantrine medication in Nigeria since it is one of the most commonly used ACT drug.
Source: Revista da Sociedade Brasileira de Medicina Tropical - Category: Tropical Medicine Source Type: research
We reported three cases of possible parasite resistance to artemether-lumefantrine therapy. All subjects had complete parasite clearance when treated with other antimalarial drugs. This observation necessitates the urgent need to re-evaluate artemether-lumefantrine medication in Nigeria since it is one of the most commonly used ACT drug.
Source: Revista da Sociedade Brasileira de Medicina Tropical - Category: Tropical Medicine Source Type: research
We reported three cases of possible parasite resistance to artemether-lumefantrine therapy. All subjects had complete parasite clearance when treated with other antimalarial drugs. This observation necessitates the urgent need to re-evaluate artemether-lumefantrine medication in Nigeria since it is one of the most commonly used ACT drug.
Source: Revista da Sociedade Brasileira de Medicina Tropical - Category: Tropical Medicine Source Type: research
We reported three cases of possible parasite resistance to artemether-lumefantrine therapy. All subjects had complete parasite clearance when treated with other antimalarial drugs. This observation necessitates the urgent need to re-evaluate artemether-lumefantrine medication in Nigeria since it is one of the most commonly used ACT drug.
Source: Revista da Sociedade Brasileira de Medicina Tropical - Category: Tropical Medicine Source Type: research
[Cameroon Tribune] President Biya yesterday October 09, 2019 joined other Heads of State, governments and delegates at the Lyon Convention Centre to step up the fight against the three killer diseases.
Source: AllAfrica News: Malaria - Category: Infectious Diseases Source Type: news
Funding Opportunity RFA-AI-19-059 from the NIH Guide for Grants and Contracts. The purpose of this initiative is to stimulate basic research, discovery, and early translational research to enable and accelerate the generation of highly efficacious pre-erythrocytic stage, sporozoite-based vaccines. Cross-fertilization and collaboration among investigators from malaria vaccine research and other basic research areas such as parasite biology, parasite genomics, pathogenesis, and host immunology are highly encouraged. The goal is to generate one or more promising vaccine candidates against human malaria that exhibit performan...
Source: NIH Funding Opportunities (Notices, PA, RFA) - Category: Research Source Type: funding
[Nation] Kenya will contribute $6 million (Sh623 million) to programmes to fight Aids, tuberculosis and malaria as other international donors made pledges for the next three years to help fight the epidemics.
Source: AllAfrica News: Health and Medicine - Category: African Health Source Type: news
More News: Infectious Diseases | Malaria